Evidence map›Paper›PMID 42839633›Full record

ArticleCancer reports (Hoboken, N.J.)2026

Assessment of Selected Immunophenotypic Markers in Childhood Non-Hodgkin's Lymphomas in Ghana: A Possible Tool for Effective Stratification of Patients and Assessment of Survival Outcomes.

Samuel Asamoah Sakyi, Bernard Gyan, Ernest Adankwah, Ernest Kwasi Adjei, Vivian Paintsil, David Kwabena Adu, Manu Akwasi Owusu, Clement Binwatin Dagungong, Muniru Mohammed Tanko, Kervin Edinam Zogli and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Samuel Asamoah SakyiDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0000-0001-5168-4762
Bernard GyanDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0009-0005-3019-1578
Ernest AdankwahDepartment of Medical Laboratory Technology, Faculty of Allied Health Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0000-0001-5710-7325
Ernest Kwasi AdjeiDepartment of Pathology, Laboratory Services Directorate, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Vivian PaintsilPediatric Oncology Unit, Child Health Directorate, Komfo Anokye Teaching Hospital, Kumasi, Ghana.ORCID https://orcid.org/0000-0002-8965-0549
David Kwabena AduDepartment of Medical Diagnostics, College of Health and Well-Being, Kintampo, Ghana.
Manu Akwasi OwusuDepartment of Medical Diagnostics, College of Health and Well-Being, Kintampo, Ghana.ORCID https://orcid.org/0009-0009-0825-8528
Clement Binwatin DagungongDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.
Muniru Mohammed TankoDepartment of Biomedical Laboratory Sciences, School of Allied Health Sciences, University for Development Studies, Tamale, Ghana.ORCID https://orcid.org/0000-0002-0487-8465
Kervin Edinam ZogliDepartment of Biomedical Laboratory Sciences, School of Allied Health Sciences, University for Development Studies, Tamale, Ghana.
Alfred EffahDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0000-0002-7096-4652
Samuel Kwame Sopuruchi AgomuoDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0009-0008-9784-9970
Samuel KwartengDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.
Beatrice NyantakyiwaaDepartment of Clinical Microbiology, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0009-0003-5963-9490
Edward Osei GyimahDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0009-0000-2584-999X
Harriet Yeboaa DiawuoDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0009-0000-9710-2481
George Oduro OwusuFaculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0009-0002-1453-6634
Ebenezer SenuDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0000-0002-2973-8952
Oscar Simon Olympio MensahDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0009-0000-0714-6684
Stephen OpokuDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, USA.ORCID https://orcid.org/0000-0002-1949-2338
Benjamin AmoaniDepartment of Biomedical Science, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Central Region, Ghana.ORCID https://orcid.org/0000-0002-4086-3033
Linda Ahenkorah FondjoDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.ORCID https://orcid.org/0000-0003-0252-3190

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-Hodgkin lymphomas (NHL) represent a heterogeneous group of malignancies with varying molecular and immunophenotypic characteristics. In Ghana, NHL is the third most common childhood cancer, highlighting the need for precise diagnostic approaches to improve survival rates. The identification of immunophenotypic biomarkers expressed by both healthy and neoplastic cells of the immune systems has been shown to provide information on the diagnostic and prognostic characterization of tumors leading to personalized treatment of NHL. We evaluated the immunophenotypic profiles of pediatric NHL and their correlation with survival outcomes.

aimsThis study aimed to evaluate the immunophenotypic characteristics of three subtypes of non-Hodgkin lymphoma (NHL) and their associated survival outcomes among children diagnosed at Komfo Anokye Teaching Hospital, Kumasi.

methodsIn this retrospective study, 38 NHL patients were recruited from the Komfo Anokye Teaching Hospital from 2018 to 2022. Clinico-pathological characteristics and treatment outcome were obtained in patients' folders. Formalin fixed paraffin embedded tissues were histologically examined and immunohistochemistry performed using monoclonal antibodies targeting CD3, CD25 and BCL-2. The Kaplan-Meier method was used to obtain survival curves and compared by the log-rank test. Statistical analysis was performed using SPSS (version 26.0) and XLSTAT.

resultsFemales accounted for 55.3% of cases, with most patients being under 10 years. Within the first-year post-diagnosis, 30.6% of children died, and 27.8% abandoned treatment. BCL-2 was the most frequently expressed marker (55.3%), with co-expression observed across all lymphoma types and age groups. Survival analysis was performed on 21/38 participants with complete follow-up data. The median survival time was 22 months (95% CI: 3.96-40.11), with survival rates declining from 76% at 10 months to 20% at 40 months. Factors significantly associated with poor survival included BCL-2 expression (poorer survival) and extranodal spread (p < 0.05).

conclusionThe survival rate for NHL patients in Ghana is very low. BCL-2 was the most expressed marker, significantly influencing survival outcomes. The extent of tumor spread also influenced survival outcomes. Identifying prognostic factors for early diagnosis and treatment is essential to improving survival outcomes for NHL patients in this setting.

Indexed as

Biomarkers, TumorLymphoma, Non-HodgkinAdolescentCD3 ComplexChildChild, PreschoolFemaleGhanaHumansImmunophenotypingInfantMalePrognosisProto-Oncogene Proteins c-bcl-2Retrospective StudiesSurvival RateBCL2 protein, humanBiomarkers, TumorCD3 ComplexProto-Oncogene Proteins c-bcl-2BCL‐2CD25CD3immunohistochemistryimmunophenotypingnon‐Hodgkin lymphomasurvival

Identifiers

PMID42839633
PMCPMC13643208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.